2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Non-Biological Therapies, Palliative Care, Biological Processes, Pathogenesis, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, MDS, MPN, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4424 Defining current unmet needs and patient management considerations in essential thrombocythemia (ET): A US Delphi consensus

Anthony Michael Hunter, MD, Brian Chernak, MD2, Luke Fletcher, MD3, Linda Resar I, MD4
1 Emory University School of Medicine, Atlanta, Georgia, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 Willamette Valley Cancer and Research, Eugene, OR, Eugene, Oregon, United States
4 Johns Hopkins Medicine, Balitmore, Maryland, United States

Introduction

Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm (MPN) associated with thrombotic and hemorrhagic complications, symptom burden, and risk of progression to myelofibrosis or acute myeloid leukemia. Although multiple therapeutic options are available, treatment approaches vary considerably in clinical practice, and this variability is likely to increase as new therapies emerge, Key areas of controversy in ET management include the role of molecular response as a treatment endpoint, the optimal management of younger patients and women of child-bearing age, long-term goals of therapy, and the definition of disease modification. Here, we applied a structured, multidisciplinary consensus process within US practice settings to establish expert consensus on current unmet needs and contemporary management considerations in ET.

 

Methods

We conducted a two-round US-based Delphi consensus project. A targeted literature review (PubMed, Google) informed a steering committee (SC) meeting comprised of four hematology and hematology-oncology experts (the authors) in April 2026. The SC developed 51 initial consensus statements spanning five domains: (A) treatment goals (symptom control, thrombo-hemorrhagic risk, and disease progression); (B) shared decision-making with patients; (C) defining and achieving disease modification; (D) optimizing treatment for younger patients and women of childbearing age; and (E) supporting and managing treatment-related adverse events. Statements were independently reviewed by each SC member before being shared with a broader panel of US hematologists/oncologists with relevant specialism and clinical experience. The panel was recruited from the SC member’s own professional networks using a purposive sampling method.  Agreement with statements was assessed using a 6-point Likert scale, ranging from ‘strongly agree’ to ‘strongly disagree’. Consensus was defined as ≥75% agreement (agreement responses as a % of overall response). Statements that did not reach consensus were flagged for further discussion.   

 

Results

At the time of data cutoff, 27 responses were received at time of data cut from the expert panel in Round 1 (14 hematologist-oncologists, 12 hematologists, and 1 oncologist) across academic (18/27), community (7/27), and specialized MPN center settings (2/27); over 80% of respondents reported caring for more than 10 ET patients annually. Of the 51 statements tested, 50 (98%) achieved consensus (≥75% agreement), with most reaching 93-100% agreement across all five domains. Statements reaching full (100%) agreement included: “Treatment goals in ET should be individualized, balancing symptom control, thrombosis prevention, and risk of disease progression”; “Patients should be informed that ET is defined as a malignancy, but this should be done with sensitivity”;  “Pregnant patients or those planning pregnancy should preferentially receive interferon-based therapy”; and “Hydroxyurea-associated toxicities, including mucocutaneous complications, should be monitored and may necessitate treatment modification”. Within Domain C, panelists agreed (93-100%) that a disease-modifying therapy (DMT) is one that prolongs life expectancy, prevents or delays disease progression, alters the natural history of the disease, prevents the acquisition of additional mutations, and reduces variant allele frequency (JAK2 V617F/CALR/MPL). Although agreement was lower, 78% agreed that “Reduction in mutant allele burden should be considered an appropriate surrogate marker of disease modification in the absence of longitudinal study data”. The sole statement that did not achieve consensus was that “a DMT in ET is one that reduces leukocytosis” (56%), potentially due to the relative scarcity of leukocytosis in ET.

 

Conclusions

This Delphi consensus demonstrated broad agreement relevant to five key domains of ET management, including individualized treatment goals, shared decision-making, and multiple complementary clinical and molecular characteristics of disease modification. However, only moderate consensus (78%) was reached on using mutant allele burden reduction as a surrogate marker of disease modification, underscoring the need for robust longitudinal data to establish whether molecular response translate into meaningful clinical benefits in ET.

Anthony Michael Hunter, MD: Incyte - Honoraria; Disc Medicine - Honoraria; Blueprint Medicines Corporation, a wholly owned subsidiary of Sanofi - Honoraria; BMS - Honoraria; Cogent Biosciences - Honoraria; Merck - Honoraria; Geron - Honoraria; Novartis - Honoraria; Cycle Pharmaceutical - Honoraria; GSK - Honoraria; Sobi - Honoraria; PharmaEssentia - Honoraria; Incyte - Research Funding; PharmaEssentia - Research Funding; Disc Medicine - Research Funding; Shenzen TargetRx - Research Funding; Syntrix Biosystems - Research Funding; Janssen - Research Funding; Telios Pharma - Research Funding; Ascentage Pharma - Research Funding; Novartis - Research Funding; Blueprint Medicines Corporation, a wholly owned subsidiary of Sanofi - Research Funding; Cogent Biosciences - Research Funding; Sumitomo - Research Funding; BMS - Consultancy (Includes expert testimony); PharmaEssentia - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); Cogent Biosciences - Consultancy (Includes expert testimony); Cycle Pharmaceutical - Consultancy (Includes expert testimony); Blueprint Medicines Corporation, a wholly owned subsidiary of Sanofi - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Disc Medicine - Consultancy (Includes expert testimony); Geron - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Karyopharm - Consultancy (Includes expert testimony)